ELRIG's US Debut to Bridge Atlantic for Drug Discovery Innovation

CAMBRIDGE, MA – April 14, 2026 – In a significant move to foster transatlantic collaboration, the European Laboratory Research & Innovation Group (ELRIG) has announced its inaugural US conference, Drug Discovery USA 2026. The event, scheduled for June 16–17 at Pfizer’s Cambridge, Massachusetts campus, marks a major expansion for the not-for-profit organization, extending its renowned open-access model to one of the world's most vibrant life science hubs.

For two days, the conference will bring together leading minds from academia and industry across Europe and the United States. The core focus will be on the frontiers of pharmaceutical science: emerging multifunctional small molecules and novel biologic modalities designed to modulate proteins once considered “undruggable.” By making the event free to attend, ELRIG aims to democratize access to cutting-edge science and create a unique melting pot for innovation.

A New Model for Scientific Exchange

ELRIG’s entry into the US market is distinguished by its foundational principle: providing high-quality science at no cost to the attendee. This stands in stark contrast to the conventional conference landscape in the United States, where registration fees for premier scientific events can run into thousands of dollars, often creating a significant barrier for students, early-career professionals, and researchers from smaller academic labs or biotech startups.

As a volunteer-led, not-for-profit organization, ELRIG has built its reputation in Europe by hosting accessible, high-caliber events that prioritize community and knowledge sharing over commercial gain. The launch of Drug Discovery USA 2026 directly applies this ethos to the competitive Boston/Cambridge ecosystem, which hosts numerous high-profile but costly industry gatherings. This open-access approach is expected to attract a diverse audience, fostering a more inclusive environment for networking and collaboration.

Sanj Kumar, CEO of ELRIG, emphasized the strategic importance of this expansion. “ELRIG Drug Discovery USA expands the reach of our renowned, free-to-attend events, providing US-based scientists with easier access high-quality science and networking opportunities,” he stated. Kumar also noted the event's dual role, serving as “a bridgehead for international life science companies to engage with the wider community.”

Targeting the Scientific Frontier

The scientific program for the inaugural conference delves into some of the most challenging and promising areas of modern medicine. The agenda is designed to address a long-standing obstacle in the field: the fact that approximately 85% of the human proteome remains beyond the reach of conventional drugs. The conference will spotlight two key areas of innovation aimed at conquering these “difficult-to-drug” targets.

First is the exploration of emerging multifunctional small molecules. This category includes revolutionary approaches like targeted protein degraders (TPDs) and molecular glues. Unlike traditional inhibitors that simply block a protein's function, these sophisticated molecules hijack the cell’s own machinery to eliminate disease-causing proteins entirely. This offers a powerful and precise way to intervene in disease processes, opening new avenues for precision medicine.

The second major theme is novel biologic modalities. This broad field moves beyond traditional antibodies to include highly engineered proteins, multi-specific binders, peptide scaffolds, and RNA-based therapeutics like siRNA and mRNA. These advanced platforms, born from breakthroughs in protein engineering and chemical biology, are providing versatile toolkits to modulate complex biological pathways that were previously inaccessible. The conference will also highlight hybrid strategies, such as antibody-drug conjugates (ADCs), which combine the targeting precision of biologics with the potent cell-killing power of small molecules.

A Blueprint for Collaboration

The ambitious goal of hosting a free, high-impact conference in a major US hub is made possible through a powerful network of partnerships. Pfizer, a global biopharmaceutical leader, is not only providing its state-of-the-art Cambridge facility as the venue but is also a key partner in the event’s mission. This collaboration underscores a growing industry trend toward fostering open innovation and supporting the broader scientific ecosystem.

Drug Discovery News (DDN) has also joined as a partner, leveraging its media reach to connect the event with a global audience. This collaborative model, which relies on industry support to eliminate financial barriers for attendees, serves as a powerful blueprint for future scientific events.

The scientific credibility of the conference is further cemented by its distinguished directors. The program is being curated by a trio of industry and academic leaders: Professor Aled Edwards of the Structural Genomics Consortium (SGC), a pioneer of open science drug discovery; Dr. Marija Tadin-Strapps, Head of Discovery Network at Pfizer; and Dr. Swarna Balasubramanian, a Director of Search & Evaluation at AstraZeneca. Their collective expertise ensures the speaker lineup and scientific content will represent the cutting edge of research from both academic and commercial perspectives.

Cultivating Future Innovation

Beyond its high-level scientific sessions, Drug Discovery USA 2026 is structured to actively nurture the next generation of scientific talent and groundbreaking ideas. A dedicated poster award will recognize the contributions of Early Career Professionals, providing them with a platform to present their research and gain visibility within the community.

Furthermore, the event will feature a “Breakthrough Zone,” a specially designated exhibition area where start-up companies can showcase their science and technology to potential partners, investors, and collaborators. This initiative directly aligns with ELRIG’s mission to create a dynamic and interconnected ecosystem where nascent ideas can flourish.

By combining world-class science with an unwavering commitment to accessibility, ELRIG’s first foray into the American market is more than just another conference. It represents a deliberate effort to build a more connected, inclusive, and collaborative global drug discovery community, where the free exchange of knowledge can accelerate the journey toward new medicines.